Literature DB >> 19524378

Hormonal contraceptive regimens in the perimenopause.

Sarah M R Hardman1, Ailsa E Gebbie.   

Abstract

Perimenopausal women have low fertility but still need contraception if they are sexually active. They often have co-existing menstrual problems and menopausal symptoms. No method of contraception is contraindicated by age alone. In addition to highly effective contraception, hormonal methods offer non-contraceptive benefits which can improve quality of life for perimenopausal women. Combined hormonal oral contraception has been available for many decades. The combined vaginal ring and transdermal patch are newer methods offering alternative delivery systems but similar risk profiles to oral preparations. New combinations containing naturally occurring estrogens in place of the synthetic hormone ethinylestradiol are now available and, in theory, could be safer. The progestogen-only methods have an excellent safety profile and have a range of delivery systems and dosages to suit all. Concerns regarding loss of bone mineral density with the injectable depot medroxyprogesterone acetate continue but to date there is no evidence that this translates into higher fracture risk. Effective use of any method of contraception is strongly dependent on good counselling and support from healthcare professionals. Risks should be explained in absolute terms for each individual woman, enabling her to make an informed choice on evidence-based medicine and not influenced by ill-informed media publicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19524378     DOI: 10.1016/j.maturitas.2009.05.001

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  6 in total

1.  Impact of CD4+ lymphocytes and HIV infection on Anti-Müllerian Hormone levels in a large cohort of HIV-infected and HIV-uninfected women.

Authors:  Rebecca Scherzer; Peter Bacchetti; Geralyn Messerlian; Johanna Goderre; Pauline M Maki; David B Seifer; Kathryn Anastos; Roksana Karim; Ruth M Greenblatt
Journal:  Am J Reprod Immunol       Date:  2014-10-23       Impact factor: 3.886

2.  Reproductive factors, exogenous hormones, and pancreatic cancer risk in the CTS.

Authors:  Eunjung Lee; Pamela L Horn-Ross; Rudolph P Rull; Susan L Neuhausen; Hoda Anton-Culver; Giske Ursin; Katherine D Henderson; Leslie Bernstein
Journal:  Am J Epidemiol       Date:  2013-09-05       Impact factor: 4.897

3.  Sporadic contraceptive use and nonuse: age-specific prevalence and associated factors.

Authors:  Karen Pazol; Maura K Whiteman; Suzanne G Folger; Athena P Kourtis; Polly A Marchbanks; Denise J Jamieson
Journal:  Am J Obstet Gynecol       Date:  2014-10-08       Impact factor: 8.661

Review 4.  Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke.

Authors:  Rachel E J Roach; Frans M Helmerhorst; Willem M Lijfering; Theo Stijnen; Ale Algra; Olaf M Dekkers
Journal:  Cochrane Database Syst Rev       Date:  2015-08-27

5.  Influence of structured counseling on women's selection of hormonal contraception in Israel: results of the CHOICE study.

Authors:  Arie Yeshaya; Amos Ber; Daniel S Seidman; Bjorn J Oddens
Journal:  Int J Womens Health       Date:  2014-08-21

Review 6.  Use of Combined Oral Contraceptives in Perimenopausal Women.

Authors:  Moon Kyoung Cho
Journal:  Chonnam Med J       Date:  2018-09-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.